Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Pharmaceutical Statistics|March 9, 2013
Exact likelihood ratio and score confidence intervals for the binomial proportionMatthew C Somerville, Rebekkah S BrownArchives of Pathology & Laboratory Medicine|November 29, 2013
Comparison of Classic and International Society of Urological Pathology 2005 Modified Gleason grading using needle biopsies from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trialM Scott Lucia, David G Bostwick, Matthew C Somerville, et al.The Journal of Urology|October 2, 2012
The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trialRobert L Grubb, Gerald L Andriole, Matthew C Somerville, et al.European Journal of Cancer (Oxford, England : 1990)|June 7, 2015
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancerFranklin M Chu, Oliver Sartor, Leonard Gomella, et al.The Journal of Urology|July 17, 2007
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trialJ Curtis Nickel, Claus G Roehrborn, Michael P O'leary, et al.European Urology|November 27, 2007
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trialJ Curtis Nickel, Claus G Roehrborn, Michael P O'Leary, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Biopsy misidentification identified by DNA profiling in a large multicenter trialMichael Marberger, John D McConnell, Ivy Fowler, et al.Urology|January 26, 2005
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostateKenneth A Iczkowski, Jingxin Qiu, Junqi Qian, et al.BJU International|June 25, 2011
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE studyMichael Marberger, Stephen J Freedland, Gerald L Andriole, et al.Contemporary Clinical Trials|June 19, 2007
Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trialNeil Fleshner, Leonard G Gomella, Michael S Cookson, et al.Pageof 2